As of October 27, 2026, 10x Genomics, Inc. is a publicly traded company (Nasdaq: TXG); its largest reported holder is Fidelity (FMR), with 15.6% on Schedule 13G/A of March 6, 2026, then T. Rowe Price (11.7%). The largest insider holding is Serge Saxonov, the chief executive and a director, with 1,121,893 shares, per Form 4 of September 24, 2026 (Schedule 13G/A, March 6, 2026).
About to sign with, pay or invest in 10x Genomics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is 10x Genomics, Inc. a real, registered company?
- 10x Genomics, Inc. files with the SEC under CIK 1770787 (its SEC filings).
- Its shares are listed under the ticker TXG on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Pleasanton, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under 10x Genomics, Inc. in our court records and SEC 8-K records (as of 2026-10-27).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names ARK Invest (filed 2026-10-07).
Who are 10x Genomics, Inc.'s owners and officers?
10x Genomics, Inc.: incorporated in Delaware; business address in Pleasanton, California; industry Laboratory Analytical Instruments (Schedule 13G/A, 2026-10-07).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-07 | Ark Investment Management LLC | 5.22% |
| Schedule 13G, 2026-09-08 | T. Rowe Price Associates, Inc. | 11.7% |
| Schedule 13G/A, 2026-08-14 | Ark Investment Management LLC | 8.56% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 5.24% |
| Schedule 13G, 2026-04-28 | Vanguard Portfolio Management | 5.93% |
| Schedule 13G/A, 2026-03-25 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-03-24 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-03-06 | Fmr LLC | 15.6% |
| Schedule 13G/A, 2026-01-08 | Fmr LLC | 10.8% |
| Schedule 13G/A, 2025-11-13 | Amova Asset Management Americas, Inc. | 4.7% |
| Schedule 13G/A, 2025-11-05 | Fmr LLC | 8.1% |
| Schedule 13G/A, 2025-11-04 | Ark Investment Management LLC | 10.39% |
Want the whole picture on 10x Genomics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on 10x Genomics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 10x Genomics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own 10x Genomics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 1,121,893 shares, 1,050,249 held directly and 71,644 indirectly (Form 4, 2026-09-24).
- , a director: 488,182 shares (Form 4, 2026-08-26).
- , a director: 328,436 shares (Form 4, 2026-09-08).
- , the chief financial officer: 316,344 shares (Form 4, 2026-09-11).
- , a director: 85,877 shares (Form 4, 2026-06-08).
Shares only: the company's cover page does not give one share count for a single class, so no percentage is worked out.
How much has 10x Genomics, Inc. raised?
No fundraising or offering filing from 10x Genomics, Inc. is on file with us.
Keep reading
More on 10x Genomics, Inc. and the records around it.
10x Genomics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Amova Asset Management Americas, Inc. also filed stake reports on 3 other companies: Ibotta, Inc. (Feb 2026), Nextdoor Holdings, Inc. (Feb 2026), Arcturus Therapeutics Holdings Inc. (Nov 2025)
- Sumitomo Mitsui Trust Group, Inc. also filed stake reports on 6 other companies: ORIX Corporation (Jul 2026), GCM Grosvenor Inc. (Apr 2026), Schrodinger, Inc. (Apr 2026)
- ARK Investment Management LLC also filed stake reports on 20 other companies: Twist Bioscience Corp (Sep 2026), 908 Devices Inc. (Aug 2026), Beam Therapeutics Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/10x-genomics